These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Comparison between Liu Y; Dong Y; Liu J; Zhang X; Lin M; Xu B Prostate; 2021 Dec; 81(16):1329-1336. PubMed ID: 34516670 [TBL] [Abstract][Full Text] [Related]
6. Semiquantitative Parameters in PSMA-Targeted PET Imaging with Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557 [No Abstract] [Full Text] [Related]
7. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814 [TBL] [Abstract][Full Text] [Related]
8. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT. Cornelis FH; Durack JC; Morris MJ; Scher HI; Solomon SB Clin Nucl Med; 2017 Dec; 42(12):e516-e518. PubMed ID: 29099733 [TBL] [Abstract][Full Text] [Related]
9. An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. Rowe SP; Gorin MA; Chu LC; Pienta KJ; Pomper MG; Ross AE; Macura KJ Clin Nucl Med; 2017 Oct; 42(10):e441-e443. PubMed ID: 28806262 [TBL] [Abstract][Full Text] [Related]
10. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304 [TBL] [Abstract][Full Text] [Related]
12. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Gorin MA; Marashdeh W; Ross AE; Allaf ME; Pienta KJ; Pomper MG; Rowe SP Nucl Med Commun; 2017 Sep; 38(9):795-798. PubMed ID: 28704341 [TBL] [Abstract][Full Text] [Related]
13. PSMA-Based Detection of Prostate Cancer Bone Lesions With ¹⁸F-DCFPyL PET/CT: A Sensitive Alternative to (⁹⁹m)Tc-MDP Bone Scan and Na¹⁸F PET/CT? Rowe SP; Mana-Ay M; Javadi MS; Szabo Z; Leal JP; Pomper MG; Pienta KJ; Ross AE; Gorin MA Clin Genitourin Cancer; 2016 Feb; 14(1):e115-8. PubMed ID: 26603549 [No Abstract] [Full Text] [Related]
14. Prostate Cancer Local Recurrence Detected With Both Gorin MA; Pienta KJ; Pomper MG; Rowe SP Urology; 2017 Sep; 107():e9-e10. PubMed ID: 28641974 [TBL] [Abstract][Full Text] [Related]
15. Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents. Endepols H; Morgenroth A; Zlatopolskiy BD; Krapf P; Zischler J; Richarz R; Muñoz Vásquez S; Neumaier B; Mottaghy FM BMC Cancer; 2019 Jun; 19(1):633. PubMed ID: 31242896 [TBL] [Abstract][Full Text] [Related]
16. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322 [TBL] [Abstract][Full Text] [Related]
17. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [ Sahakyan K; Li X; Lodge MA; Werner RA; Bundschuh RA; Bundschuh L; Kulkarni HR; Schuchardt C; Baum RP; Pienta KJ; Pomper MG; Ross AE; Gorin MA; Rowe SP Mol Imaging Biol; 2020 Feb; 22(1):181-189. PubMed ID: 31115751 [TBL] [Abstract][Full Text] [Related]
18. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT. Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635 [TBL] [Abstract][Full Text] [Related]